Clinical Trials List
Protocol NumberVedolizumab-4013
2016-08-01 - 2020-12-31
Others
Terminated1
ICD-9556.9
Ulcerative colitis, unspecified
Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn’s Disease
-
Trial Applicant
PPD DEVELOPMENT (HK) LIMITED
-
Sponsor
Takeda Development Center Americas, Inc.
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Kaohsiung Municipal Gangshan Hospital
Chairman/Global PI
吳登強
Co-Principal Investigator
Audit
CRO
Co-Principal Investigator
- Chien-Yu Lu Digestive System Department
- Wen-Hung Hsu Digestive System Department
- Chao-Hung Kuo Digestive System Department
- I-CHEN WU Digestive System Department
- Yu-Chung Su Digestive System Department
- Huang-Ming Hu Digestive System Department
- Fang-Jung Yu Yu Digestive System Department
The Actual Total Number of Participants Enrolled
0 Stop recruiting
Condition/Disease
Ulcerative Colitis and Crohn’s Disease
Objectives
A
Test Drug
Vedolizumab IV
Active Ingredient
Vedolizumab IV
Dosage Form
Injection
Dosage
300
Endpoints
A
Inclution Criteria
A
Exclusion Criteria
A
The Estimated Number of Participants
-
Taiwan
1 participants
-
Global
484 participants
